➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Medtronic
Johnson and Johnson
Colorcon
McKinsey

Last Updated: August 13, 2020

DrugPatentWatch Database Preview

ABSORICA LD Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Absorica Ld, and when can generic versions of Absorica Ld launch?

Absorica Ld is a drug marketed by Sun Pharm and is included in one NDA. There are two patents protecting this drug.

This drug has seventeen patent family members in nine countries.

The generic ingredient in ABSORICA LD is isotretinoin. There are thirteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the isotretinoin profile page.

US ANDA Litigation and Generic Entry Outlook for Absorica Ld

A generic version of ABSORICA LD was approved as isotretinoin by AMNEAL PHARMS NY on September 29th, 2017.

  Start Trial

Summary for ABSORICA LD
Drug patent expirations by year for ABSORICA LD
Drug Prices for ABSORICA LD

See drug prices for ABSORICA LD

Recent Clinical Trials for ABSORICA LD

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Institute (NCI)Phase 2
Children's Oncology GroupPhase 2
Ranbaxy Inc.Phase 4

See all ABSORICA LD clinical trials

Pharmacology for ABSORICA LD
Drug ClassRetinoid

US Patents and Regulatory Information for ABSORICA LD

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm ABSORICA LD isotretinoin CAPSULE;ORAL 211913-001 Nov 5, 2019 RX Yes No   Start Trial   Start Trial Y   Start Trial
Sun Pharm ABSORICA LD isotretinoin CAPSULE;ORAL 211913-004 Nov 5, 2019 RX Yes No   Start Trial   Start Trial Y   Start Trial
Sun Pharm ABSORICA LD isotretinoin CAPSULE;ORAL 211913-002 Nov 5, 2019 RX Yes No   Start Trial   Start Trial Y   Start Trial
Sun Pharm ABSORICA LD isotretinoin CAPSULE;ORAL 211913-006 Nov 5, 2019 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Sun Pharm ABSORICA LD isotretinoin CAPSULE;ORAL 211913-004 Nov 5, 2019 RX Yes No   Start Trial   Start Trial Y   Start Trial
Sun Pharm ABSORICA LD isotretinoin CAPSULE;ORAL 211913-001 Nov 5, 2019 RX Yes No   Start Trial   Start Trial Y   Start Trial
Sun Pharm ABSORICA LD isotretinoin CAPSULE;ORAL 211913-002 Nov 5, 2019 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Mallinckrodt
Merck
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.